Adaptive Biotechnologies Corp expected to post a loss of 33 cents a share - Earnings Preview

Adaptive Biotechnologies

30/07/2024 22:16

* Adaptive Biotechnologies Corp  ADPT.OQ   ADPT.O  is
expected
to show a fall in quarterly revenue when it reports  results on
August 1 for the period ending June 30 2024
    * The Seattle Washington-based  company is expected to
report a
21.0% decrease in revenue to $38.664 million from $48.93 million
a year ago, according to the mean estimate from 7 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Adaptive Biotechnologies
Corp
is for a loss of 33 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Adaptive
Biotechnologies Corp is $6.00​, above​ its last closing price
of $4.44. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.34       -0.34      -0.33     Beat    3.3
 Dec. 31 2024  -0.33       -0.33      -0.30     Beat    9.4
 Sep. 30 2023  -0.35       -0.34      -0.35     Missed  -3.3​
 Jun. 30 2023  -0.35       -0.35      -0.33     Beat    4.8
 ​​Mar.        -0.37       -0.38      -0.40     Missed  -6.2
 31 2023                                                
 Dec. 31 2022  -0.34       -0.35      -0.28     Beat    19.2​
 Sep. 30 2022  -0.37       -0.38      -0.32     Beat    14.9
 Jun. 30 2022  -0.41       -0.43      -0.37     Beat    14
 This summary was machine generated July 30 at 21:16 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)